Harrow, Inc. Litigation Settlement, Expense
Harrow, Inc. (HROW) reported Litigation Settlement, Expense of $450.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LitigationSettlementExpense · last filed 2018-03-08
- Harrow, Inc. litigation settlement, expense for fiscal 2017 was $450.00K.
| Period end | Litigation Settlement, Expense 12 month |
|---|---|
| 2017-12-31 | $450.00K 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |